SecBot SecBot
8-K ·Filed May 12, 2026

MGNX

MACROGENICS INC
BULLISH
Impact 7/10
Horizonmonths Processed6mo ago SEC0001125345-26-000035
8-K material event: Items 1.01
Actionable Insight ▲ Bullish

The sale provides MacroGenics with significant non-dilutive capital to extend its cash runway and focus on its clinical pipeline. Monitor closing conditions (regulatory and landlord consents) and any updates on pipeline catalysts. The transaction removes a capital-intensive CDMO operation, improving operational focus and financial flexibility.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$3.52
T+0 close · May 12, 2026 · via day close
Latest settled
+13.92%
T+60 · $4.01
Vs SPY
+9.54%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 12 $3.52entry
  2. T+1 · 6mo ago −1.99%α −2.56% · $3.45
  3. T+5 · 6mo ago +23.58%α +23.50% · $4.35
  4. T+20 · 5mo ago +9.94%α +11.67% · $3.87
  5. T+60 · 3mo ago +13.92%α +9.54% · $4.01
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

MacroGenics entered into a definitive agreement to sell its GMP manufacturing operations (CDMO business) to Bora Pharmaceuticals for a $122.5 million upfront cash payment, subject to customary closing adjustments and up to $5 million in contingent milestones. The transaction, expected to close in Q3 2026, provides non-dilutive capital to fund the company's R&D pipeline while retaining manufacturing access via a supply agreement.

Key Financial Metrics

Deal Value
$122.5M
Deal Type
acquisition

Key Facts

  • Base purchase price of $122.5 million in cash at closing, subject to working capital and indebtedness adjustments.
  • Up to $5 million in additional contingent payments based on manufacturing milestones through 2028.
  • Transaction includes transfer of the Rockville, MD manufacturing facility (11,000L capacity) and Frederick, MD warehouse.
  • Approximately 140 MacroGenics employees expected to be hired by Bora.
  • Closing expected in the third quarter of 2026, subject to customary conditions including landlord consents and regulatory approvals.
  • MacroGenics will enter into a manufacturing and supply agreement with Bora for clinical and commercial supply post-closing.
  • Transaction approved by both companies' boards of directors.

Financial Impact

Upfront cash consideration of $122.5 million, equating to ~65% of MacroGenics' pre-announcement market cap of $188 million. Potential additional $5 million in contingent payments.

cashrevenueoperating expenses

Risk Factors

  • Risk that closing conditions (including required consents) may not be satisfied, delaying or preventing the transaction.
  • Potential for lower-than-expected net proceeds after transaction fees and working capital adjustments.
  • Contingent earnout may not be realized, capping additional upside at $5 million.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
62% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001125345-26-000035
Exhibit: exhibit991_pressrelease.htm0001125345-26-000035
Document: mgnx-20260511.htm0001125345-26-000035
Document: 0001125345-26-000035-index-headers.html0001125345-26-000035
Document: 0001125345-26-000035-index.html0001125345-26-000035
Document: 0001125345-26-000035.txt0001125345-26-000035

Track record

21 reports on MGNX

Performance horizon

3 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +130.41% at T+60 after the Feb 28, 2026 report. 7 of 8 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $2.22 Now $2.17 −2.25% settles Feb 12
  2. Nov 13, 20263d ago 8-K Neutral 4/10 Entry $2.31 Now $2.17 −6.06% settles Feb 12
  3. Nov 12, 20264d ago Press Release Bearish 5/10 Entry $2.20 Now $2.17 +1.36% settles Feb 11
  4. Nov 3, 202613d ago 3 Neutral 1/10 Entry $2.31 Now $2.17 −6.06% settles Feb 2
  5. Nov 3, 202613d ago 3 Neutral 1/10 Entry $2.31 Now $2.17 −6.06% settles Feb 2
  6. Nov 3, 202613d ago 8-K Neutral 2/10 Entry $2.31 Now $2.17 −6.06% settles Feb 2
  7. Oct 26, 202621d ago Press Release Bullish 6/10 Entry $2.19 Now $2.17 −0.91% settles Jan 22
  8. Oct 23, 202624d ago 8-K Bullish 7/10 Entry $2.19 Now $2.17 −0.91% settles Jan 22
  9. Oct 22, 202625d ago 144 Neutral 2/10 Entry $2.25 Now $2.17 −3.56% settles Jan 21
  10. Oct 15, 20264w ago Press Release Neutral 3/10 Entry $3.25 Now $2.17 −33.23% settles Jan 13
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 37m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 12, 2026